Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome
Open Access
- 3 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (5), 1480-1484
- https://doi.org/10.1038/s41375-021-01171-y
Abstract
No abstract availableFunding Information
- Japan Agency for Medical Research and Development (18ck0106435h0001)
- Health and Labor Sciences Research Grants
This publication has 14 references indexed in Scilit:
- Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971Blood, 2011
- Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemiaBlood, 2011
- Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemiaBlood, 2010
- Risk factors for early death in neonates with Down syndrome and transient leukaemiaBritish Journal of Haematology, 2008
- Treatment and prognostic impact of transient leukemia in neonates with Down syndromeBlood, 2008
- Incidence and clinical implications of GATA1 mutations in newborns with Down syndromeBlood, 2007
- A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481Blood, 2006
- Immunophenotype of Down Syndrome Acute Myeloid Leukemia and Transient Myeloproliferative Disease Differs Significantly from Other Diseases with Morphologically Identical or Similar BlastsKlinische Padiatrie, 2005
- Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesisBlood, 2003
- Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndromeNature Genetics, 2002